The FDA's take on transparency

26 February 2018
fda-blog-700

By Dr Nicola Davies

In 2009, the US Food and Drug Administration outlined steps to improve its transparency program in three phases.1

Dr Nicola Davies in her monthly FDA Blog for The Pharma Letter notes that Phase I, FDA Basics, launched in January 2010, is an online platform where members of the public are granted access to information concerning the FDA and its activities.2 FDA Basics for Industry was also launched to provide information on the design, manufacture, labeling, marketing, and testing of products.3 In May of the same year, Phase II, a report which provided information on products and firms regulated by the FDA, was released. This was followed in 2011 by Phase III, a report on the transparency operations and decision-making process of the FDA.4 While transparency is a significant concern for the FDA, many feel the Administration’s transparency initiatives fall short of where they could be.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical